PMID- 22422591
OWN - NLM
STAT- MEDLINE
DCOM- 20121109
LR  - 20161125
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 98
IP  - 11
DP  - 2012 Jun
TI  - Plasma asymmetric dimethylarginine and mortality in patients with acute 
      decompensation of chronic heart failure.
PG  - 860-4
LID - 10.1136/heartjnl-2011-301372 [doi]
AB  - OBJECTIVES: To investigate the prognostic value of circulating levels of 
      asymmetric dimethylarginine (ADMA) in patients with acute decompensation of (New 
      York Heart Association (NYHA) class III/IV) chronic heart failure and reduced 
      left ventricular ejection fraction. DESIGN: Single-centre prospective 
      observational study. SETTING: Tertiary referral centre. PATIENTS: A total of 651 
      consecutive and eligible hospitalised patients were studied. Patients were 
      divided into four groups according to the quartiles of circulating levels of ADMA 
      upon presentation. MAIN OUTCOME MEASURES: Incidence of in-hospital (or 7-day in 
      the case of prolonged hospitalisation), 31-day and 1-year cardiac mortality were 
      the pre-specified study end points. RESULTS: Cumulative rates of in-hospital, 
      31-day and 1-year cardiac mortality were 10.6%, 18.7% and 36.4%, respectively. 
      There was a gradual increased risk of in-hospital (p(for trend)=0.011), 31-day 
      (p(for trend)=0.044) and 1-year (p(for trend)<0.001) mortality with increasing 
      ADMA quartiles. After adjustment for possible confounders, patients at the 
      highest ADMA quartile were at significantly higher risk for in-hospital 
      (p=0.042), 31-day (p=0.032) and 1-year (p<0.001) mortality than those in the 
      lowest quartile. CONCLUSIONS: According to the present results, an elevated 
      circulating level of ADMA is a strong independent predictor of short-term and 
      long-term mortality in patients with acute decompensation of NYHA class III/IV 
      chronic heart failure and reduced left ventricular ejection fraction. ADMA levels 
      upon presentation may confer enhanced risk stratification in this setting.
FAU - Zairis, Michael N
AU  - Zairis MN
AD  - Koletti 56, Piraeus, 18537, Greece. zairis66@otenet.gr
FAU - Patsourakos, Nikoloas G
AU  - Patsourakos NG
FAU - Tsiaousis, George Z
AU  - Tsiaousis GZ
FAU - Theodossis Georgilas, Anastassios
AU  - Theodossis Georgilas A
FAU - Melidonis, Andreas
AU  - Melidonis A
FAU - Makrygiannis, Stamatis S
AU  - Makrygiannis SS
FAU - Velissaris, Dimitrios
AU  - Velissaris D
FAU - Batika, Pelagia C
AU  - Batika PC
FAU - Argyrakis, Kyriakos S
AU  - Argyrakis KS
FAU - Tzerefos, Stavros P
AU  - Tzerefos SP
FAU - Prekates, Athanasios A
AU  - Prekates AA
FAU - Foussas, Stefanos G
AU  - Foussas SG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120315
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Biomarkers)
RN  - 0 (Enzyme Inhibitors)
RN  - 63CV1GEK3Y (N,N-dimethylarginine)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
CIN - Heart. 2012 Jun;98(11):831-2. PMID: 22581731
MH  - Aged
MH  - Arginine/*analogs & derivatives/blood
MH  - Biomarkers/blood
MH  - Endothelium, Vascular/physiopathology
MH  - Enzyme Inhibitors/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Greece/epidemiology
MH  - Heart Failure/*blood/classification/diagnosis/*mortality/physiopathology
MH  - Hospitals, University
MH  - Humans
MH  - Incidence
MH  - Inpatients/statistics & numerical data
MH  - Kaplan-Meier Estimate
MH  - Length of Stay/statistics & numerical data
MH  - Male
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Stroke Volume
MH  - Survival Rate
EDAT- 2012/03/17 06:00
MHDA- 2012/11/10 06:00
CRDT- 2012/03/17 06:00
PHST- 2012/03/17 06:00 [entrez]
PHST- 2012/03/17 06:00 [pubmed]
PHST- 2012/11/10 06:00 [medline]
AID - heartjnl-2011-301372 [pii]
AID - 10.1136/heartjnl-2011-301372 [doi]
PST - ppublish
SO  - Heart. 2012 Jun;98(11):860-4. doi: 10.1136/heartjnl-2011-301372. Epub 2012 Mar 
      15.